Perfuse Therapeutics

San Francisco, United States Founded: 2018 • Age: 8 yrs Acquired By Bayer
Developer of therapies to treat eye disorders

About Perfuse Therapeutics

Perfuse Therapeutics is a company based in San Francisco (United States) founded in 2018 by Sevgi Gurkan was acquired by Bayer in May 2026.. Perfuse Therapeutics offers products and services including Endothelin Antagonist. Perfuse Therapeutics operates in a competitive market with competitors including Bausch & Lomb, Dopavision, Appasamy Associates, Katalyst Surgical and Lamellar, among others.

  • Headquarter San Francisco, United States
  • Founders Sevgi Gurkan
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Perfuse Therapeutics, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
    Bayer

    & 1 more

  • Employee Count
    Employee Count
  • Acquired by
    Bayer

    (May 06, 2026)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Perfuse Therapeutics

Perfuse Therapeutics offers a comprehensive portfolio of products and services, including Endothelin Antagonist. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Improves blood flow to retina to treat glaucoma and diabetic retinopathy.

People of Perfuse Therapeutics
Headcount 1-10
Employee Profiles 8
Employee Profiles
People
Maria Zaretskaia, M.D.
Principal Scientist
People
Andrew Melie
Analytical Scientist
People
Christopher Romeo
Principal Scientist, Device And Formulation
People
Heather Schmitt
Clinical Development Scientist

Unlock access to complete

Funding Insights of Perfuse Therapeutics

  • Total Funding
  • Total Rounds 1
  • Last Round
  • First Round
  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2020 Amount Series A - Perfuse Therapeutics Valuation Access Industries
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Perfuse Therapeutics

Perfuse Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer and Access Industries. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investment and holding company controlled by Len Blavatnik
Founded Year Domain Location
Life science solutions for healthcare and agriculture are delivered.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Perfuse Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Perfuse Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Perfuse Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Perfuse Therapeutics

Perfuse Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bausch & Lomb, Dopavision, Appasamy Associates, Katalyst Surgical and Lamellar, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Ophthalmic pharmaceuticals and instruments are developed for eye care.
domain founded_year HQ Location
Digital therapeutics for myopia are developed via retinal light stimulation.
domain founded_year HQ Location
Ophthalmic instruments and pharmaceutical products are developed for eye care.
domain founded_year HQ Location
Titanium ophthalmic surgical instruments are manufactured and repaired.
domain founded_year HQ Location
Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies
domain founded_year HQ Location
Precision instruments for eye surgery are designed and manufactured.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Perfuse Therapeutics

Trial Okayed for Glaucoma Treatment Implant
Technewslit3 years ago

Frequently Asked Questions about Perfuse Therapeutics

When was Perfuse Therapeutics founded?

Perfuse Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Perfuse Therapeutics located?

Perfuse Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Who is the current CEO of Perfuse Therapeutics?

Sevgi Gurkan is the current CEO of Perfuse Therapeutics. They have also founded this company.

What does Perfuse Therapeutics do?

Perfuse Therapeutics was founded in 2018 in San Francisco, United States, within the biotechnology sector. Focus is placed on developing treatments for eye disorders, including glaucoma and retinal diseases. A proprietary technology is employed to enhance retinal perfusion, targeting improved outcomes in these conditions. Operations center on therapeutic innovation for ocular health applications.

Who are the top competitors of Perfuse Therapeutics?

Perfuse Therapeutics's top competitors include Bausch & Lomb, Appasamy Associates and Katalyst Surgical.

What products or services does Perfuse Therapeutics offer?

Perfuse Therapeutics offers Endothelin Antagonist.

Who are Perfuse Therapeutics's investors?

Perfuse Therapeutics has 2 investors. Key investors include Bayer, and Access Industries.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available